Breast cancer experts answer key questions on selecting, sequencing, and managing ADCs in HR-positive, HER2-positive, and triple-negative disease.
Feature|Articles|June 26, 2025
Ongoing Trials Aim to Remove Carboplatin from TCHP and Reduce Treatment Cycles in HER2+ Breast Cancer
Author(s)Ashley Chan
Fact checked by: Kyle Doherty
As the HER2-positive breast cancer landscape continues to evolve, the omission of carboplatin in TCHP could drive significant change.
Advertisement
Advertisement
Within the past decade, the HER2-positive breast cancer landscape has demonstrated significant improvements. However, coming off the heels of the
Related to this article
Trastuzumab deruxtecan plus pertuzumab improved systemic and intracranial outcomes in HER2-positive breast cancer with baseline brain metastases.
The European Commission approved T-DXd for patients with HER2+ breast cancer who have residual invasive disease after neoadjuvant treatment.
Most of the survival time accrued with RP1 plus nivolumab in the IGNYTE trial was spent in good health among patients with advanced melanoma after anti–PD-1 therapy.
VET3-TGI produced responses in injected and non-injected lesions without dose-limiting toxicities in the phase 1/1b STEALTH-001 trial.
IL-1β blockade with canakinumab was well tolerated and reduced nodule size in patients with high-risk indeterminate pulmonary nodules.
VGX-3100 met its composite primary end point in the phase 3 HPV-303CHN trial, supporting a nonsurgical treatment approach for HPV-16/18–associated cervical HSIL.
EVX-01 plus pembrolizumab generated sustained neoantigen-specific T-cell responses in advanced melanoma.
Advertisement
Advertisement